Mesoblast Limited ( MESO) - Key Metrics
MESO Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q4 | $0.27 | -$0.07 | -$0.05 | -$0.05 |
| 2026Q3 | $0.27 | -$0.07 | -$0.03 | -$0.03 |
| 2026Q2 | $0.20 | -$0.16 | -$0.12 | -$0.12 |
| 2026Q1 | $0.20 | -$0.16 | -$0.12 | -$0.12 |
| 2025Q4 | $0.06 | -$0.21 | -$0.12 | -$0.12 |
MESO Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q4 | 0% | -50.49 |
| 2026Q3 | 0% | -57.39 |
| 2026Q2 | 0% | -29.10 |
| 2026Q1 | 0% | -25.98 |
| 2025Q4 | 0% | -12.78 |
MESO
Price: $13.87
52 week price:
Earnings Per Share: -0.44 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: Australia
Volume: 45251
Ebitda: -19.5 millionMarket Capitalization: 1.8 billion